|
TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors. |
|
|
Honoraria - AstraZeneca; Genentech/Roche; Medtronic |
Consulting or Advisory Role - AstraZeneca; Takeda |
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Endocyte (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Jounce Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novocure (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Medtronic; Takeda |
|
|
Research Funding - Exelixis (Inst) |
Travel, Accommodations, Expenses - Immunomedics |
|
|
Employment - Immunomedics |
Leadership - Immunomedics |
Stock and Other Ownership Interests - Immunomedics |
Travel, Accommodations, Expenses - Immunomedics |
|
|
Employment - Immunomedics; Mallinckrodt |
Stock and Other Ownership Interests - Immunomedics; Mallinckrodt |
|
|
Employment - Immunomedics; Novartis |
Stock and Other Ownership Interests - Immunomedics |
|
|
Employment - Bristol-Myers Squibb; Immunomedics |
Leadership - Bristol-Myers Squibb; Immunomedics |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Immunomedics |
Consulting or Advisory Role - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck; Tesaro |
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Merck (Inst); Puma Biotechnology (Inst); R-Pharm (Inst); Tesaro (Inst) |